Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 13, 2017 20:05 pm UTC| Business
DUBLIN, Ireland, Sept. 13, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and...
Franklin Limited Duration Income Trust Announces Sources of Monthly Dividend Distribution
Sep 13, 2017 20:05 pm UTC| Business
SAN MATEO, Calif., Sept. 13, 2017 -- The Franklin Limited Duration Income Trust (NYSE:FTF) (CUSIP 35472T101) has declared a dividend of $0.1067 per common share payable September 15, 2017, to shareholders of record as...
CytomX to Present at the Cantor Fitzgerald Healthcare Conference
Sep 13, 2017 20:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the...
Lam Research Announces 2017 Supplier Excellence Award Recipients
Sep 13, 2017 20:05 pm UTC| Business
FREMONT, Calif., Sept. 13, 2017 -- Lam Research Corp. (Nasdaq:LRCX), a global supplier of innovative wafer fabrication equipment and services to the semiconductor industry, today announced it has recognized seven...
Curis Announces Proposed Public Offering of Common Stock
Sep 13, 2017 20:05 pm UTC| Business
LEXINGTON, Mass., Sept. 13, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced its intention to offer and sell up to 20 million shares of its common stock in an underwritten public offering...
YRC Worldwide Provides Quarter-To-Date Operating Data for Third Quarter 2017
Sep 13, 2017 20:03 pm UTC| Business
OVERLAND PARK, Kan., Sept. 13, 2017 -- YRC Worldwide Inc. (NASDAQ:YRCW) reported certain operating metrics for the first two months of third quarter 2017. At YRC Freight, July 2017 tonnage per day was essentially flat...
Epizyme Announces Proposed Public Offering of Common Stock
Sep 13, 2017 20:01 pm UTC| Business
CAMBRIDGE, Mass., Sept. 13, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it intends to offer and sell $120 million of shares...